RxSight (RXST) Cost of Revenue (2020 - 2026)

RxSight (RXST) has reported Cost of Revenue for 7 consecutive years, with $7.4 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 22.69% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $29.3 million (down 29.77% YoY), and the FY2025 full-year result was $31.5 million, down 23.21% from the prior year.
• Cost of Revenue improved to $7.4 million in Q1 2026 per RXST's latest filing, from $7.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $11.4 million in Q4 2024 and bottomed at $5.2 million in Q1 2022.
• Historically, Cost of Revenue has averaged $8.4 million across 5 years, with a median of $8.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue surged 119.07% in 2022, then slumped 39.44% in 2025.
• Over 5 years, Cost of Revenue stood at $8.7 million in 2022, then climbed by 26.08% to $10.9 million in 2023, then advanced by 4.58% to $11.4 million in 2024, then tumbled by 35.72% to $7.3 million in 2025, then gained by 0.68% to $7.4 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $7.4 million, $7.3 million, and $6.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.